drugset / Trial / NCT00792493

Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741

NCT00792493 ↗

Phase 1 Completed 51 enrolled Orion Corporation, Orion Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of escalating multiple doses of ORM-12741 in healthy volunteers

Timeline

Start
2008-12
Primary completion
2009-06
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ORM-12741 Small molecule — —

Indications

No indication recorded.